March 31, 2012 --Chongqing Huapont Pharma plans to raise $146 million in a private placement to fund four capital projects; Lee’s Pharmaceutical signed a term sheet with RegeneRx to in-license the China rights for three Thymosin Beta 4-based molecules; GlaxoSmithKline and Hanmi Pharma agreed to co-develop and co-market drugs in Korea and China; Hubei Minkang Pharma signed a MoU to acquire a 30% to 51% interest in Hubei Merryclin Pharma; Bayer HealthCare extended its research partnership with Beijing’s Tsinghua University for another three years; GE Healthcare will seek to increase its China revenues by expanding into rural markets with new products; Roche will “significantly” reduce the price the company charges in India for two expensive biotech cancer drugs; and Novasep opened a new 21,400 square foot facility in Shanghai’s Pudong district. More details….
Stock Symbols: (SHE: 002004) (OTCBB: RGRX) (NYSE: GSK) (OTCBB: HBMK) (Xetra: BAY) (NYSE: GE) (VX: ROG)
